The consumer healthcare company's new Intense formula showed stronger early effects than its existing product in a 223-person study
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the Eroxon erectile dysfunction gel, has reported positive results from a home user trial of both its existing product and a new, stronger formulation called Eroxon Intense.
The study, conducted over four weeks with 223 male participants aged 18 to 59, found the product delivered high efficacy rates in men with mild to moderate erectile dysfunction (ED), a condition affecting the ability to achieve or maintain an erection.
Participants reported satisfaction with erection hardness in 70% of sexual encounters using the standard Eroxon gel, rising marginally to 71% with the Intense formula.
Erections lasting long enough for intercourse were recorded in 84% of encounters with Eroxon and 85% with Intense.
Both products also produced a clinically significant improvement on the International Index of Erectile Function (IIEF-EF), the most widely used clinical measure of erection quality, with results at least matching those from the phase III trial that secured US regulatory approval for Eroxon.
The key distinction between the two formulas was timing: Intense produced a statistically significantly stronger sensory effect within the first two minutes of application, which the company said would appeal particularly to younger users seeking a faster response.
The trial also found that partner-applied use increased effectiveness and erection maintenance across both products.
Futura said it had already filed a "special" 510K application with the US Food and Drug Administration for Eroxon Intense, and expects regulatory approval in both the US and Europe in the first half of 2026.
The company added that the results supported a more targeted marketing approach, focusing on consumers under 60 with mild to moderate ED and encouraging partner involvement during foreplay.
Ken James, executive director and head of research and development, said the findings provided "further validation of our formulation science" as the company progressed Intense through the regulatory process.